ES2124256T3 - Arilmorfolina, preparacion y uso. - Google Patents

Arilmorfolina, preparacion y uso.

Info

Publication number
ES2124256T3
ES2124256T3 ES92908819T ES92908819T ES2124256T3 ES 2124256 T3 ES2124256 T3 ES 2124256T3 ES 92908819 T ES92908819 T ES 92908819T ES 92908819 T ES92908819 T ES 92908819T ES 2124256 T3 ES2124256 T3 ES 2124256T3
Authority
ES
Spain
Prior art keywords
arylmorfoline
preparation
treatment
hydrogen
morpholins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92908819T
Other languages
English (en)
Inventor
Nariman Bomanshaw Mehta
Grady Evan Boswell
James Leroy Kelley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2124256T3 publication Critical patent/ES2124256T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

NUEVAS MORFOLINAS DE LA FORMULA (I) Y SUS SALES, EN DONDE R Y R1 SON CADA UNO BIEN HIDROGENO O BIEN FLUOR Y R2 ES HIDROGENO O METILO. LOS COMPUESTOS PRESENTAN UNA GRAN VARIEDAD DE USOS EN MEDICINA PARA EL TRATAMIENTO DE SERES HUMANOS, EN PARTICULAR PARA EL TRATAMIENTO DE TRASTORNOS MENTALES TALES COMO LA DEPRESION.
ES92908819T 1991-04-23 1992-04-22 Arilmorfolina, preparacion y uso. Expired - Lifetime ES2124256T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919108629A GB9108629D0 (en) 1991-04-23 1991-04-23 Heterocyclic pharmaceutical compounds,preparation and use

Publications (1)

Publication Number Publication Date
ES2124256T3 true ES2124256T3 (es) 1999-02-01

Family

ID=10693740

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92908819T Expired - Lifetime ES2124256T3 (es) 1991-04-23 1992-04-22 Arilmorfolina, preparacion y uso.

Country Status (17)

Country Link
US (2) US5648347A (es)
EP (1) EP0583271B1 (es)
JP (1) JP3130040B2 (es)
AT (1) ATE173252T1 (es)
AU (1) AU668863B2 (es)
CA (1) CA2108967C (es)
DE (1) DE69227583T2 (es)
DK (1) DK0583271T3 (es)
ES (1) ES2124256T3 (es)
FI (1) FI934680A0 (es)
GB (1) GB9108629D0 (es)
HU (1) HU219458B (es)
IE (1) IE921260A1 (es)
NZ (1) NZ242421A (es)
PT (1) PT100415B (es)
WO (1) WO1992018489A1 (es)
ZA (1) ZA922910B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9108629D0 (en) * 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
EP1047428B1 (en) 1998-01-21 2007-06-20 Glaxo Group Limited Use of morpholinol for the treatment of sexual dysfunction
US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
FR2796069B3 (fr) * 1999-07-09 2001-08-24 Sanofi Synthelabo Nouveaux procedes de preparation de derives de 2-(2- arylmorpholin-2-yl)ethanol substitues, enantiomeriquement purs, et composes intermediaires utiles dans ces procedes
SI1572214T1 (sl) * 2002-12-10 2010-07-30 Pfizer Ltd Derivati morfolina za uporabo kot dopaminski agonisti pri zdravljenju med drugim spolne disfunkcije
GB0228787D0 (en) * 2002-12-10 2003-01-15 Pfizer Ltd Morpholine dopamine agonists
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
JP5952267B2 (ja) 2010-05-21 2016-07-13 リサーチ・トライアングル・インスティチュート 薬物依存を処置するためのヒドロキシブプロピオン類似体（政府支援研究または開発）
EP2571858B1 (en) * 2010-05-21 2018-06-20 Research Triangle Institute Phenylmorpholines and analogues thereof
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2997469A (en) * 1961-08-22 Preparation of substituted
GB851311A (en) * 1958-04-02 1960-10-12 Geigy Ag J R Morpholine compounds and their production
US3117967A (en) * 1962-04-02 1964-01-14 Smith Kline French Lab 2-biphenylyl-2-hydroxy-morpholinium halides
GB1336732A (en) * 1970-10-28 1973-11-07 Istituto Gentili Spa Pisa Diethanolamine derivatives
IE50355B1 (en) * 1979-10-20 1986-04-02 Wyeth John & Brother Ltd Morpholine derivatives
FR2517305B1 (fr) * 1981-12-01 1985-10-25 Lafon Labor Nouveaux derives de 2-phenyl-morpholine et leur utilisation en therapeutique
FR2553410B1 (fr) * 1983-10-14 1986-05-16 Lafon Labor Nouveaux derives de 2-tolyl-morpholine utiles en therapeutique
FR2553411B1 (fr) * 1983-10-14 1986-08-01 Lafon Labor Derives de 2-halogenophenyl-morpholine, procede de preparation et utilisation en therapeutique
FR2553413B1 (fr) * 1983-10-17 1986-03-21 Lafon Labor Derives de 4-alkyl-2-hydroxy-3-methyl-2-phenyl-morpholine, procede de preparation et utilisation en therapeutique
GB8417170D0 (en) * 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
US4803200A (en) * 1987-10-02 1989-02-07 A. H. Robins Company, Incorporated Substituted dialkanolamines, sulfur analogs and condensed 1,4-oxazine derivatives thereof in viral disease treatment
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
GB9108629D0 (en) * 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use

Also Published As

Publication number Publication date
FI934680L (fi) 1993-10-22
IE921260A1 (en) 1992-11-04
FI934680A7 (fi) 1993-10-22
CA2108967C (en) 2002-10-08
HUT70531A (en) 1995-10-30
PT100415A (pt) 1993-06-30
HU219458B (hu) 2001-04-28
AU1575392A (en) 1992-11-17
JP3130040B2 (ja) 2001-01-31
ATE173252T1 (de) 1998-11-15
DE69227583D1 (de) 1998-12-17
GB9108629D0 (en) 1991-06-12
WO1992018489A1 (en) 1992-10-29
NZ242421A (en) 1994-10-26
ZA922910B (en) 1994-01-24
PT100415B (pt) 1999-08-31
HU9303000D0 (en) 1994-01-28
AU668863B2 (en) 1996-05-23
EP0583271A1 (en) 1994-02-23
DE69227583T2 (de) 1999-04-01
DK0583271T3 (da) 1999-07-26
US5760224A (en) 1998-06-02
FI934680A0 (fi) 1993-10-22
JPH06506675A (ja) 1994-07-28
EP0583271B1 (en) 1998-11-11
CA2108967A1 (en) 1992-10-24
US5648347A (en) 1997-07-15

Similar Documents

Publication Publication Date Title
ES2123064T3 (es) Uso de melatonina en pequeñas dosis orales como somnifero.
DE3779500D1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
ES2124256T3 (es) Arilmorfolina, preparacion y uso.
ES2145922T3 (es) Compuestos espiro-azabiciclicos utiles en terapia.
ES2152222T3 (es) Sulfonamidas, su preparacion y su uso como medicamento e intermedio.
ES2084944T3 (es) Amidas terapeuticas.
ES2080739T3 (es) Nitro-compuestos insecticidamente activos.
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
ATE69376T1 (de) Haarwuchsmittel.
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
ES2153420T3 (es) Derivados de amida biciclica y uso como relajantes musculares de los mismos.
ES2085865T3 (es) Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean.
MX9207494A (es) 4(5)-amino-1,8-naftiridinas substituidas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
AR019053A1 (es) Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen
AR007088A1 (es) 2,4-diaminopirimidinas sustituidas, compuestos intermedios utilizados en su preparacion, procedimiento para la preparacion de dichas 2,4-diaminopirimidinas sustituidas, medicamentos que las contienen y empleos de dichas pirimidinas
IT1221826B (it) Preparato per uso topico per il trattamento terapeutico dell impotentia coeundi
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
ATE132859T1 (de) 2-aminopyrimidin-4-carboxamid-derivate, deren herstellung und deren therapeutische anwendung
ATE38151T1 (de) Bestaendige 5-adenosyl-l-methionin-salze enthaltende, pharmazeutische zusammensetzungen fuer orale anwendung.
ES2054718T3 (es) El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.
ATE80616T1 (de) Prostaglandin e1-derivate und ihre therapeutische anwendung.
ES2038216T3 (es) Procedimiento para la preparacion de 5-(3-alquil-5-t-butil-4-hidroxi-fenil)-2-amino-6h-1,3,4-tiadazinas y su empleo.
DK0634396T3 (da) Aminosyrederivater og deres anvendelse som enkeltfalinaseinhibitorer
ES2181702T3 (es) Derivados de melatonina para su uso en el tratamiento de enfermedad es del sueño.
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 583271

Country of ref document: ES